---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-045033"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2023-12-15T23:59:59+00:00"
generated_at: "2026-06-07T11:37:10.892963+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics reports 2023 annual meeting voting results; two Class II directors elected

## Summary
- Robert B. Stein, MD, PhD elected with 974,293 votes for, 56,765 withheld; Jennifer Buell, PhD elected with 963,089 for, 67,969 withheld.
- Ratification of MaloneBailey LLP as auditor passed with 2,324,009 for, 9,482 against, 2,451 abstain.
- Directors Stein and Buell will serve Class II terms until 2026 annual meeting; board composition updated.
- Total shares present at meeting: 2,336,032 out of 4,330,959 entitled to vote.

## SEC filing metadata
- accession: 0001493152-23-045033
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2023-12-15T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000149315223045033/0001493152-23-045033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000149315223045033/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-045033
- JSON: https://secwatch.observer/filing/0001493152-23-045033.json
- Plain text: https://secwatch.observer/filing/0001493152-23-045033.txt

## Key facts
- Shareholder Votes
  Protagenic Therapeutics, Inc.new shareholders approved Ratification of MaloneBailey LLP as the independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-13 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-12-13
  source text: Proposal Two: The stockholders ratified the selection of MaloneBailey LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Abstain 2,324,009 9,482 2,451
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000149315223045033/0001493152-23-045033-index.htm
- Shareholder Votes
  Protagenic Therapeutics, Inc.new shareholders approved Election of Class II directors at the 2023-12-13 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-12-13
  source text: Proposal One: The stockholders elected each of the following individuals as a Class II director to serve their terms until the Company’s 2026 Annual Meeting of Stockholders, and until their respective successors are duly elected and qualified; Name For Against Withheld Broker Non-Votes Robert B. Stein, MD, PhD 974,293 - 56,765 1,304,974 Jennifer Buell, PhD 963,089 - 67,969 1,304,974
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000149315223045033/0001493152-23-045033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.